54439-75-7

Basic information

• Product Name: 2-Chloro-4-hydroxybenzaldehyde 98%
• Synonyms: Benzaldehyde, 2-chloro-4-Methoxy-
• CAS NO: 54439-75-7
• Molecular Formula: C₈H₇ClO₂
• Molecular Weight: 170.6
• Mol File: 54439-75-7.mol
• Article Data: 9

Chemical Properties

• Melting Point: 64℃
• Boiling Point: 272.5 °C at 760 mmHg
• Flash Point: 118.6 °C
• Appearance: /
• Density: 1.404 g/cm³
• Vapor Pressure: 0.007mmHg at 25°C
• Refractive Index: 1.564
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 2-Chloro-4-hydroxybenzaldehyde 98%(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-4-hydroxybenzaldehyde 98%(54439-75-7)
• EPA Substance Registry System: 2-Chloro-4-hydroxybenzaldehyde 98%(54439-75-7)

Safety Data

• Hazardous Substances Data: 54439-75-7(Hazardous Substances Data)

Usage

General Description

2-Chloro-4-hydroxybenzaldehyde 98% is a chemical compound with the molecular formula C7H5ClO2. It is a white to off-white solid with a purity of 98%. 2-Chloro-4-hydroxybenzaldehyde 98% is commonly used in organic synthesis and pharmaceutical research as an intermediate in the production of various pharmaceuticals and agrochemicals. It is also used as a building block in the synthesis of various aromatic compounds. Due to its reactivity and versatility, 2-Chloro-4-hydroxybenzaldehyde 98% is a valuable compound in chemical research and development. It should be handled with care and stored in a cool, dry place away from direct sunlight and heat sources.

InChI:InChI=1/C8H7ClO2/c1-11-7-3-2-6(5-10)8(9)4-7/h2-5H,1H3

Upstream product

• 74-90-8 hydrogen cyanide 
• 2845-89-8 1-chloro-3-methoxy-benzene 
• 5568-33-2 2-chloro-4-nitrobenzaldehyde 
• 124-41-4 sodium methylate 
• 2186-92-7 p-Anisaldehyde dimethyl acetal 
• 123-11-5 4-methoxy-benzaldehyde 
• 121-86-8 2-chloro-4-nitrotoluene 
• 42533-63-1 1-(bromomethyl)-2-chloro-4-nitrobenzene 
• 56962-11-9 2-chloro-4-hydroxybenzaldehyde 
• 74-88-4 methyl iodide 
• 108-43-0 3-monochlorophenol 

Downstream Products

• 111086-67-0 C₃₀H₂₆Cl₂N₂O₄ 
• 134029-52-0 (Z)-1-(2-chloro-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene 
• 134054-80-1 (E)-1-(2-chloro-4-methoxyphenyl)-2-(3,4,5-trimethoxyphenyl)ethene 
• 16817-45-1 1-(2-chloro-4-methoxyphenyl)propan-2-one 
• 663944-66-9 2,2'-dichloro-4,4'-dimethoxybenzoin 
• 127666-99-3 2-chloro-4-methoxylbenzonitrile 
• 868861-13-6 N-(4-methoxyphenyl)-2-chloro-4-methoxybenzamidine 
• 935750-26-8 2-(2-chloro-4-methoxyphenyl)-1,4-bis(4-methoxyphenyl)-1H-imidazole 
• 935750-28-0 2-(2-chloro-4-methoxyphenyl)-1,4-bis(4-methoxyphenyl)-5-methyl-1H-imidazole 
• 935750-31-5 2-(2-chloro-4-methoxyphenyl)-5-ethyl-1,4-bis(4-methoxyphenyl)-1H-imidazole 
• 935750-30-4 2,4-bis(2-chloro-4-methoxyphenyl)-1-(4-methoxyphenyl)-5-methyl-1H-imidazole 
• 935750-36-0 2-(2-chloro-4-methoxyphenyl)-1,4-bis(4-methoxyphenyl)-5-phenyl-1H-imidazole 
• 663944-60-3 2,2'-dichloro-4,4'-dimethoxybenzil 
• 334018-24-5 (2-chloro-4-methoxyphenyl)methanol 

Relevant articles and documents

BENZOCYCLOBUTANE DERIVATIVES USEFUL AS DUAL SGLT1/SGLT2 MODULATORS

The present invention is directed to benzocyclobutane derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by SGLT activity, more particularly dual SGLT1/2 activity. More particularly, the compounds of the present invention are useful in the treatment of for example, Type II diabetes mellitus, Syndrome X, and complications and symptoms associated with said disorders.

1-SUBSTITUTED-3- BETA-D-GLUCOPYRANOSYLATED NITROGENOUS HETERO- CYCLIC COMPOUNDS AND MEDICINES CONTAINING THE SAME

A compound having an SGLT1 and/or SGLT2 inhibitory activity which is usable as an agent for the prevention or treatment of diabetes, postprandial hyperglycemia, impaired glucose tolerance, diabetic complications, obesity, etc. It is a 1-substituted-3-(β-D

PYRAZOLO [1,5-ALPHA] PYRIMIDINYL DERIVATIVES USEFUL AS CORTICOTROPIN-RELEASING FACTOR (CRF) RECEPTOR ANTAGONISTS

CRF receptor antagonists are disclosed which may have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in mammals. The CRF receptor antagonists of this invention have the following structure: (I); and pharmaceutically acceptable salts, esters, solvates, stereoisomers and prodrugs thereof, wherein R1, R2a, R2b, Y, Het, n, o, R6, Ar and R7 are as defined herein. Compositions containing a CRF receptor antagonist in combination with a pharmaceutically acceptable carrier are also disclosed, as well as methods for use of the same.